Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma
Open Access
- 14 February 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 11 (1), 1-12
- https://doi.org/10.1038/s41467-020-14639-9
Abstract
Predicting the outcome of immunotherapy treatment in melanoma patients is challenging. Alterations in genes involved in antigen presentation and the interferon gamma (IFNγ) pathway play an important role in the immune response to tumors. We describe here that the overexpression of PSMB8 and PSMB9, two major components of the immunoproteasome, is predictive of better survival and improved response to immune-checkpoint inhibitors of melanoma patients. We study the mechanism underlying this connection by analyzing the antigenic peptide repertoire of cells that overexpress these subunits using HLA peptidomics. We find a higher response of patient-matched tumor infiltrating lymphocytes against antigens diferentially presented after immunoproteasome overexpression. Importantly, we find that PSMB8 and PSMB9 expression levels are much stronger predictors of melanoma patientsʼ immune response to checkpoint inhibitors than the tumors’ mutational burden. These results suggest that PSMB8 and PSMB9 expression levels can serve as important biomarkers for stratifying melanoma patients for immune-checkpoint treatment.This publication has 48 references indexed in Scilit:
- The Cancer Genome Atlas Pan-Cancer analysis projectNature Genetics, 2013
- Simultaneous alignment and clustering of peptide data using a Gibbs sampling approachBioinformatics, 2012
- Seq2Logo: a method for construction and visualization of amino acid binding motifs and sequence profiles including sequence weighting, pseudo counts and two-sided representation of amino acid enrichment and depletionNucleic Acids Research, 2012
- A MAGE‐C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapyInternational Journal of Cancer, 2011
- Exome sequencing identifies GRIN2A as frequently mutated in melanomaNature Genetics, 2011
- Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I moleculesProceedings of the National Academy of Sciences of the United States of America, 2010
- Dissecting Interferon-Induced Transcriptional Programs in Human Peripheral Blood CellsPLOS ONE, 2010
- MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantificationNature Biotechnology, 2008
- NetMHCpan, a method for MHC class I binding prediction beyond humansImmunogenetics, 2008
- CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigensNucleic Acids Research, 2008